JP Morgan Chase’s Thorne Healthtech, Inc. Common Stock THRN Stock Holding History

JP Morgan Chase’s Portfolio THRN Stock Details THRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-9,102	Closed	-$92.7K	–	8084
2023 Q3	$92.7K	Sell	9,102 -2,088	-19%	-$15.9K	﹤0.01%	5522
2023 Q2	$52.6K	Buy	11,190 +205	+2%	+$942	﹤0.01%	5703
2023 Q1	$50K	Buy	10,985 +3,202	+41%	+$14.1K	﹤0.01%	5697
2022 Q4	$28K	Buy	7,783 +431	+6%	+$1.91K	﹤0.01%	5779
2022 Q3	$35K	Hold	7,352	–	–	﹤0.01%	5658
2022 Q2	$36K	Sell	7,352 -5,764	-44%	-$35K	﹤0.01%	5755
2022 Q1	$83K	Buy	13,116 +9,488	+262%	+$51.1K	﹤0.01%	5599
2021 Q4	$23K	Buy	+3,628	New	+$28.4K	﹤0.01%	6186

JP Morgan Chase's THRN Position: Q4 2023 in Review

JP Morgan Chase sold out of Thorne Healthtech, Inc. Common Stock (THRN) in Q4 2023, closing a stake of 9,102 shares — an estimated $92.7K sold.

JP Morgan Chase first reported a position in THRN in Q4 2021 and held it in 8 quarters. The position peaked at $92.7K in Q3 2023. 0 funds tracked by Wall St. Rank hold THRN as of Q4 2023.

JP Morgan Chase reported no remaining Thorne Healthtech, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
JP Morgan Chase sold 9,102 Thorne Healthtech, Inc. Common Stock shares in Q4 2023, an estimated $92.7K.
JP Morgan Chase first reported a position in Thorne Healthtech, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
JP Morgan Chase's Thorne Healthtech, Inc. Common Stock position peaked at $92.7K in Q3 2023.
0 funds tracked by Wall St. Rank held Thorne Healthtech, Inc. Common Stock as of Q4 2023.

Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.